# US 2002/0058648 A1 · Estrogenic substances combined with cruciferous indole compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0058648 A1
- Document ID: US20020058648A1
- Status: Published application
- Kind: A1
- Application number: 09/991,516
- Filed: 2001-11-10
- Published: 2002-05-16
- Earliest claimed: 2000-11-13
- Inventors: Milton Hammerly
- Web page: https://patentgrep.com/patent/US20020058648A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are medicinal compositions of matter that comprise an estrogenic medication component and a cruciferous indole component (indole 3-carbinol, diindolylmethane, or any derivative thereof. Through use of the compositions of the invention a heretofore unobserved synergy is observed in the treatment of perimenopause, menopause or any other cause of ovarian failure. The invention also provides procedures for administering the composition to a patient who is afflicted with perimenopause, menopause or any other cause of ovarian failure.

## Claims

### Claim 1

A medicinal composition useful in estrogen replacement therapy comprising:
a) an estrogenic substance; and
b) a cruciferous indole compound component.

### Claim 2 (depends on 1)

A composition as set forth in claim 1 wherein said estrogenic substance is selected from the group consisting of: estrogen, conjugated estrogens, dienestrol, estrone, esterified estrogens, estradiol, estriol, estropipate, ethinyl estradiol, or any estrogenic derivatives of the foregoing.

### Claim 3 (depends on 1)

A composition as set forth in claim 1 wherein said cruciferous indole compound is selected from the group consisting of: indole 3-carbinol, diindolylmethane, 5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole-3-carbinol, 5-pentyl-indole-3-carbinol, 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propyloxy-indole-3-carbinol, 5-butyloxy-indole-3-carbinol, 5-amyloxy-indole-3-carbinol, N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-butyl-indole-3-carbinol, N-pentyl-indole-3-carbinol, 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole-3-carbinol and 2-pentyl-indole-3-carbinol.

### Claim 4 (depends on 1)

A composition according to claim 1 wherein said estrogenic substance component is present in any amount between 0.005% and 99.5% by weight based upon total weight of the composition, including every hundredth percentage therebetween.

### Claim 5 (depends on 1)

A composition according to claim 1 wherein said cruciferous indole compound component is present in any amount between 0.05% and 99.5% by weight based upon total weight of the composition, including every hundredth percentage therebetween.

### Claim 6 (depends on 1)

A single-dose medicament useful in estrogen replacement therapy comprising a composition according claim 1, wherein said estrogenic substance is selected from the group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing, and wherein the quantity said cruciferous indole compound component is at least 0.5 milligrams.

### Claim 7 (depends on 6)

A single-dose medicament according to claim 6 wherein said cruciferous indole compound is indole 3-carbinol.

### Claim 8 (depends on 6)

A single-dose medicament according to claim 6 wherein said cruciferous indole compound is diindolylmethane.

### Claim 9 (depends on 1)

A single-dose medicament useful in estrogen replacement therapy comprising a composition according claim 1, wherein said estrogenic substance is selected from the group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing, said estrogenic substance being present in a quantity of between 0.10 milligrams and 50 milligrams, including every milligram therebetween, and wherein the quantity said cruciferous indole compound component is selected from the group consisting of: indole 3-carbinol and diindolylmethane, and wherein said cruciferous indole compound component is present in an amount of between 0.5 and 300 milligrams, including every milligram therebetween.

### Claim 10 (depends on 1)

A single-dose medicament useful in estrogen replacement therapy comprising a composition according claim 1, wherein said estrogenic substance is selected from the group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing, and wherein said estrogenic substance is present in a quantity of between 0.10 and 50 milligrams, including every hundredth milligram therebetween, and wherein the quantity of said cruciferous indole compound component is present in an amount of at least 0.5 milligrams.

### Claim 11

A medicinal composition useful in the treatment of estrogen replacement therapy comprising an estrogenic substance selected from the group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing; and further comprising indole 3-carbinol.

### Claim 12

A medicinal composition useful in the treatment of estrogen replacement therapy comprising an estrogenic substance selected from the group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing; and further comprising diindolylmethane.

### Claim 13

A method of providing estrogen replacement therapy to a patient needing same, the method comprising:
administration of a therapeutically-effective amount of a estrogenic substance in synergistic combination with a therapeutically effective amount of a cruciferous indole compound selected from the group consisting of: indole 3-carbinol; and diindolylmethane, and derivatives thereof,
wherein the estrogenic substance is administered to alleviate symptoms of estrogen deficiency, and the cruciferous indole compound is administered to increase 2-hydroxyestrogen metabolites and to decrease 16-hydroxyestrogen metabolites in said patient.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the administration is oral.

### Claim 15 (depends on 13)

A method according to claim 13 wherein the administration is parenteral.

### Claim 16 (depends on 13)

A method according to claim 13, wherein the estrogen replacement therapy medication is selected from a group consisting of: estrogen; conjugated estrogens; dienestrol; estrone; esterified estrogens; estradiol; estriol; and estropipate; ethinyl estradiol; or any estrogenic derivative of the foregoing.

### Claim 17 (depends on 13)

A method according to claim 13, wherein the estrogenic substance is compounded into a single oral unit with the cruciferous indole compound.

### Claim 18 (depends on 17)

A method according to claim 17, wherein the single oral unit is a tablet.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the single oral unit is a capsule.

### Claim 20 (depends on 13)

A method according to claim 13, wherein the estrogenic substance and the cruciferous indole compound are dissolved or suspended in oil to provide an oil suspension.

### Claim 21 (depends on 20)

A method according to claim 20 wherein said oil suspension is placed in a single oral softgelatin capsule.

### Claim 22 (depends on 13)

A method according to claim 13, wherein the estrogenic substance is formed into a first single oral unit, and the cruciferous indole compound is formed into a second single oral unit,

### Claim 23 (depends on 22)

A method according to claim 22, wherein a number of first single oral units are placed in a first container, and a number of the second single oral units are placed in a second container.

### Claim 24 (depends on 23)

The method of claim 23, wherein the first and second containers are packaged together.

### Claim 25 (depends on 22)

The method of claim 22, wherein the first and second single oral units are a tablet.

### Claim 26 (depends on 22)

The method of claim 22, wherein the first and second single oral units are a capsule.

### Claim 27 (depends on 22)

The method of claim 22, wherein the second single oral unit is a softgelatin capsule.

### Claim 28 (depends on 13)

The method of claim 13, wherein the estrogenic substance is administered orally to the patient in one daily dose of at least 0.03 milligrams per day.

### Claim 29 (depends on 13)

The method of claim 13, wherein the cruciferous indole compound is administered orally to the patient in one daily dose containing at least 0.5 milligrams of any compound selected from the group consisting of indole 3-carbinol and diindolyl methane.

### Claim 30 (depends on 22)

The method of claim 22, wherein binders and carriers are used in the first and second oral units to facilitate the administration of the estrogenic substance component and the cruciferous indole compound component.

### Claim 31 (depends on 13)

A method according to claim 13 wherein said derivatives include a compound selected from the group consisting of 5-methyl-indole-3-carbinol, 5-ethyl-indole-3-carbinol, 5-propyl-indole-3-carbinol, 5-butyl-indole-3-carbinol, 5-pentyl-indole-3-carbinol, 5-methoxy-indole-3-carbinol, 5-ethoxy-indole-3-carbinol, 5-propyloxy-indole-3-carbinol, 5-butyloxy-indole-3-carbinol, 5-amyloxy-indole-3-carbinol, N-methyl-indole-3-carbinol, N-ethyl-indole-3-carbinol, N-propyl-indole-3-carbinol, N-butyl-indole-3-carbinol, N-pentyl-indole-3-carbinol, 2-methyl-indole-3-carbinol, 2-ethyl-indole-3-carbinol, 2-propyl-indole-3-carbinol, 2-butyl-indole-3-carbinol and 2-pentyl-indole-3-carbinol.

### Claim 32

A process in estrogen replacement therapy comprising the steps of:
a) providing a combination comprising:
i) an estrogenic substance component; and
ii) a cruciferous indole compound component, and
b) introducing said composition into a human body that is afflicted with an deficiency of an estrogenic substance.

### Claim 33 (depends on 32)

A process according to claim 32 wherein the total mass of the combination introduced into said body from step b) is in the range of 0.1 milligrams and 1,000 milligrams, including every hundredth of a milligram therebetween, per introduction.

### Claim 34 (depends on 32)

The process according to claim 32 wherein said introducing is undertaken orally, buccally, dermally, enterally, parenterally, or by means of a patch.
